Coronaviridae

Pardes Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 15, 2022

CARLSBAD, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and COVID-19 disease, today reported financial results for the second quarter ended June30, 2022 and provided a business update.

Key Points: 
  • CARLSBAD, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and COVID-19 disease, today reported financial results for the second quarter ended June30, 2022 and provided a business update.
  • Research and development expenses were $20.3 million for the quarter ended June30, 2022, compared to $6.3 million for the quarter ended June30, 2021, an increase of $14.0 million.
  • General and administrative expenses were $7.6 million for the quarter ended June30, 2022, compared to $1.9 million for the quarter ended June30, 2021, an increase of $5.7 million.
  • Pardes cash and cash equivalents as of June30, 2022, were $228.6 million compared to $247.9 million as of March 31, 2022.

Senstar Recognized as One of Top Five Perimeter Intrusion Brands

Retrieved on: 
Wednesday, July 13, 2022

RAMAT GAN, Israel, July 13, 2022 /PRNewswire/ -- Senstar Technologies (NASDAQ: SNT), a world leader in video management and perimeter intrusion detection solutions, today announced that the Senstar brand has been named one of the top five perimeter intrusion brands according to a reader survey conducted by asmag.com earlier this year.

Key Points: 
  • RAMAT GAN, Israel, July 13, 2022 /PRNewswire/ -- Senstar Technologies (NASDAQ: SNT), a world leader in video management and perimeter intrusion detection solutions, today announced that the Senstar brand has been named one of the top five perimeter intrusion brands according to a reader survey conducted by asmag.com earlier this year.
  • Asmag.com surveyed its readers about the perimeter intrusion detection brands of their choice, features that played a significant role in decision-making, and services that need improvement.
  • Senstar was cited as "an established industry name in perimeter intrusion detection products," offering integrated technologies for multi-layered perimeter protection.
  • The complete article is available at Top 5 perimeter intrusion brands: 2022 asmag.com reader survey .

Catalent and MigVax Sign Agreement to Develop an Orally Disintegrating Freeze-Dried Tablet Vaccine Against COVID-19

Retrieved on: 
Tuesday, June 7, 2022

SOMERSET, N.J. and KIRYAT SHMONA, Israel, June 7, 2022 /PRNewswire-PRWeb/ -- Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, and MigVax, an Israeli biopharmaceutical company developing an oral subunit vaccine against COVID-19, today announced that they have signed a development agreement to leverage Catalent's proprietary Zydis® Bio orally disintegrating tablet (ODT) technology for delivering the MigVax-101 vaccine.

Key Points: 
  • Catalent and MigVax today announced that they have signed a development agreement to leverage Catalent's proprietary Zydis Bio orally disintegrating tablet (ODT) technology for delivering the MigVax-101 vaccine against COVID-19.
  • MigVax's lead oral vaccine program, MigVax-101, has shown positive results in preclinical tests, and in November 2021.
  • In addition, MigVax's oral approach may allow for mucosal protection, a benefit that may prove important in preventing infection.
  • Using the methods learned from the existing vaccine, MigVax's new vaccine is an oral subunit human vaccine against COVID-19 administered as a tablet.

BiondVax Announces First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, June 1, 2022

JERUSALEM, June 1, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceuticals company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today published its first quarter financial results for the quarter ended March 31, 2022 and provided a business update.

Key Points: 
  • JERUSALEM, June 1, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceuticals company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today published its first quarter financial results for the quarter ended March 31, 2022 and provided a business update.
  • Results are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.176 (NIS/$US), the rate as of the close of business on March 31, 2022.
  • Unaudited first quarter financial results will be submitted to the Securities and Exchange Commission.
  • BiondVax undertakes no obligation to revise or update any forward-looking statement for any reason.

Human SARS Coronavirus 2 RNA Dependent RNA Polymerase Drugs Development Analysis Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 17, 2022

The "Human SARS Coronavirus 2 RNA Dependent RNA Polymerase Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Human SARS Coronavirus 2 RNA Dependent RNA Polymerase Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • Human SARS Coronavirus 2 RNA Dependent RNA Polymerase (RdRp or EC 2.7.7.48) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Human SARS Coronavirus 2 RNA Dependent RNA Polymerase (RdRp or EC 2.7.7.48) targeted pipeline therapeutics.
  • The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Human SARS Coronavirus 2 RNA Dependent RNA Polymerase (RdRp or EC 2.7.7.48) targeted therapeutics development and features dormant and discontinued projects.

ALERCELL Introduces COVID-19 Rapid Antigen Test Clip and Antigen Test Collection Kits

Retrieved on: 
Thursday, March 31, 2022

ALERCELL is distributing several Antigen and PCR products including Luminostics' clip COVID rapid antigen test and antigen test collection kits that will be distributed throughout the country by the company.

Key Points: 
  • ALERCELL is distributing several Antigen and PCR products including Luminostics' clip COVID rapid antigen test and antigen test collection kits that will be distributed throughout the country by the company.
  • Operating out of Bozeman, Montana, ALERCELL works towards the discovery, development, distribution, and manufacturing of a portfolio of innovative in-vitro rapid diagnostic test kits that target the Covid-19 SARS Coronavirus.
  • ALERCELL products include a broad line of rapid test antigen systems that are manufactured, marketed, and sold worldwide.
  • The coronavirus antigen test, which may be administered at the point of care, is expected to be faster and easier than prior tests.

Fur Commission USA Statement on British Columbia Supreme Court denying B.C. mink farmers interim relief on provincial mink farming restriction

Retrieved on: 
Thursday, March 10, 2022

Supreme Court denying the province's mink farmers interim relief from a ban has been based onlimited, outdated information.

Key Points: 
  • Supreme Court denying the province's mink farmers interim relief from a ban has been based onlimited, outdated information.
  • Both the CDC and USDA have agreed that mink do not pose a significant risk in spreading SARS-CoV-2 to the public.
  • In a statement, the U.S. National Park Service noted that "the risk of getting Covid-19 from animals in the United States, including wildlife, is low.
  • TheFur Commission USAis a national, non-profit association representing U.S. mink farming families.

LINKINVAX Raises €4.350 Million in Funding

Retrieved on: 
Thursday, February 10, 2022

LinKinVax, a clinical-stage biotechnology company is announcing completion of a 4.350 million seed capital funding round.

Key Points: 
  • LinKinVax, a clinical-stage biotechnology company is announcing completion of a 4.350 million seed capital funding round.
  • LinKinVax has already risen to prominence in the French sector, with Bpifrance granting it 31 million under a Covid-related PIA PSCP program and Government Plan Relance , in May 2021.
  • LinKinVaxs innovative technology directly targets dendritic cells (DC), which play a crucial role in the immune system, stimulating and regulating immune responses.
  • LinKinVax is developing an innovative protein-based vaccine platform that can accelerate availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI).

A.L. Group Launches IN-EX Air Filters to Protect First Responders, Commuters, and Drivers Against COVID-19 And Other Airborne Viruses

Retrieved on: 
Thursday, January 20, 2022

Group , a leading provider of advanced filtration solutions, launches IN-EX, a medical-grade, scientifically-proven solution for indoor air safety.

Key Points: 
  • Group , a leading provider of advanced filtration solutions, launches IN-EX, a medical-grade, scientifically-proven solution for indoor air safety.
  • Yet transit represents just one part of the puzzlea particular emphasis needs to be placed on medical services and first responders.
  • Group has developed and launched IN-EX, the first scientifically-proven indoor air quality solution.
  • IN-EX is an easy-to-install cabin air filter which transforms your air conditioning unit into an active air purifier, applicable for cars, buses (and other public transportation), ambulances, and taxis.

Largest Study to Date on COVID19 Pregnancy Outcomes Published in American Journal of Obstetrics and Gynecology

Retrieved on: 
Friday, January 14, 2022

MESA, Ariz., Jan. 14, 2022 PRNewswire/ -- Newly published today in the American Journal of Obstetrics and Gynecology is the largest study performed thus far on the effect of the COVID19 virus in pregnancy.

Key Points: 
  • MESA, Ariz., Jan. 14, 2022 PRNewswire/ -- Newly published today in the American Journal of Obstetrics and Gynecology is the largest study performed thus far on the effect of the COVID19 virus in pregnancy.
  • "In the largest study to date, a strong connection between COVID19 infection in pregnancy and preterm birth is seen."
  • Marchand holds dual certifications from the American Board of Obstetrics and Gynecology in both general OBGYN and Minimally Invasive Gynecologic Surgery.
  • About The American Journal of Obstetrics and Gynecology:AJOG Global Reports is one of two companion titles to the highly-respected American Journal of Obstetrics and Gynecology.